185563-95-5

Upstream product

• 821-41-0 5-Hexen-1-ol 
• 185563-92-2 1Triphenylmethyl-2-phthalimidoimidazole 
• 185563-93-3 1-(triphenylmethyl)imidazole-2-ylamine 
• 185563-77-3 3-ethoxycarbonyl-5-(4-hydroxybutyl)isoxazoline 
• 185563-78-4 ethyl 5-(4-oxobutyl)isoxazoline-3-carboxylate 
• 185563-94-4 3-Ethoxycarbonyl-5-[4-(1-triphenylmethylimidazol-2-ylamino)butyl]isoxazoline 

Downstream Products

• 258845-39-5 2-(3,5-dichloro-biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-40-8 2-(3,5-dimethyl-biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-37-3 2-(2,6-dichloro-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 185564-00-5 2-(2,4,6-trimethyl-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-44-2 2-(biphenyl-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-42-0 2-(naphthalene-1-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-43-1 2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-41-9 2-benzenesulfonylamino-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 258845-45-3 2-amino-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid 
• 185563-99-9 2-(2,4,6-trimethyl-benzenesulfonylamino)-3-({5-[4-(1-trityl-1H-imidazol-2-ylamino)-butyl]-4,5-dihydro-isoxazole-3-carbonyl}-amino)-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

Isoxazolines as potent antagonists of the integrin α(v)β3

Starting with lead compound 2, we sought to increase the selectivity for α(v)β3-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent α to the carboxylate. To prepare some of the desired aminoimidazoles, a novel reductive amination utilizing a trityl-protected aminoimidazole was developed. It was found that guanidine mimetics with a wide range of pK(a)'s were potent antagonists of α(v)β3. In general, it appeared that an acylated 2-aminoimidazole guanidine mimetic imparted excellent selectivity for α(v)β3-mediated adhesion versus α(IIb)β3-mediated platelet aggregation, with selectivity of approximately 3 orders of magnitude observed for compounds 3g and 3h. It was also found in this series that the α- substituent was required for potent activity and that 2,6-disubstituted arylsulfonamides were optimal. In addition, the selective α(v)β3 antagonist 3h was found to be a potent inhibitor of α(v)β3-mediated cell migration.

Integrin receptor antagonists

This invention relates to novel heterocycle compounds including but not limited to 3-?3-?3-(imidazolin-2-yl amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-propionic acid, which are useful as antagonists of the αv β3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.